

Absorbance (AU)
0,00
0,05
0,10
0,15
0,20
Retention Time (min)
0
1
2
3
4
5
6
7
8
5,31, 1951
4,67, 1198132
3,25, 0
2,64, 0
2,53, 0
2,29, 0
2,03, 0

FIGURE 1 A



Absorbance (AU)
0,15
0,10
0,05
0,00
0
1
2
3
4
5
6
7
8
Retention Time (min)
5,28, 1337
2,61, 0
2,53, 0
2,27, 0
2,00, 0

FIGURE 1 B



Absorbance (AU)
0,16
0,14
0,12
0,10
0,08
0,06
0,04
0,02
0,00
0
1
2
3
4
5
6
7
8
Retention Time (min)
2,03, 0
2,29, 0
2,53, 0
2,64, 0
4,69, 532990
5,31, 1196

FIGURE 1 C




Absorbance (AU)
0,14
0,12
0,10
0,08
0,06
0,04
0,02
0,00
0
1
2
3
4
5
6
7
8
Retention Time (min)
2,03, 0
2,29, 0
2,51, 0
6,00, 1207

FIGURE 1 D

FIGURE 1 E


Absorbance (AU)
0,16
0,14
0,12
0,10
0,08
0,06
0,04
0,02
0,00
0
1
2
3
4
5
6
7
8
Retention Time (min)
5,12, 1330
2,32, 0



Absorbance (AU)
0,15
0,10
0,05
0,00
0
1
2
3
4
5
6
7
8
Retention Time (min)
2,03, 0
2,32, 0
2,53, 0
5,07, 1326

FIGURE 1 F



Absorbance (AU)
0,00
0,05
0,10
0,15
0,20
0
1
2
3
4
5
6
7
8
Retention Time (min)

FIGURE 1 G



Absorbance (AU)
0,20
0,15
0,10
0,05
0,00
0
1
2
3
4
5
6
7
8
Retention Time (min)
2,03, 0
2,32, 0
2,53, 0
4,32, 394631
4,85, 1167

FIGURE 2 A



Absorbance (AU)
0,20
0,15
0,10
0,05
0,00
0
1
2
3
4
5
6
7
8
Retention Time (min)
5,04, 1521
3,25, 0
2,53, 0
2,32, 0
2,03, 0

FIGURE 2 B



Absorbance (AU)
0,20
0,15
0,10
0,05
0,00
0
1
2
3
4
5
6
7
8
Retention Time (min)

FIGURE 2 C

Figure 3 A



Carbomer gel 2% (n=6)
HPMC E5 (7,95) / PEG 400 (1.98) (n=6)
HPMC E5 (7.95) / PEG 400 (3.97) (n=6)
HPMC E5 (7.95) without PEG (n=8)
HPMC E5 (6.36) / PEG 400 (3.97) (n=4)
HPMC E5 (3.97) / PEG 400 (1.98) (n=4)
HPMC E5 (3.97) / PEG 400 (3.97) (n=5)
HPMC E5 (15.91) / PEG 400 (1.98) (n=4)
HPMC E5 (15.91) / PEG 400 (3.97) (n=4)
% of cidofovir diffused
Time (hours)
0
20
40
60
80
100
120
0
1
2
3
4
5
6
7

Figure 3 B



Carbomer gel 2% (n=6)
NaCMC (3.18) / PEG 400 (1.98) (n=2)
NaCMC (4.77) without PEG (n=4)
NaCMC (4.77) / PEG 400 (1.98) (n=4)
NaCMC (4.77) / PEG 400 (3.97) (n=4)
NaCMC (6.36) / PEG 400 (1.98) (n=2)
% of cidofovir diffused
120
100
80
60
40
20
0
0
1
2
3
4
5
6
7
Time (hours)

Figure 3 C



HEC 250HX (7,95) / PEG 400 (1.98) (n=4)
Carbomer gel 2% (n=6)
HEC 250M (9.54) / PEG 400 (1.98) (n=4)
% of cidofovir diffused
120
100
80
60
40
20
0
0
1
2
3
4
5
6
7
Time (hours)

Figure 4



7100 19kV X25 1mm WD39
7082 19kV X25 1mm WD39
HPMC E5 (7.93 mg/cm²) / PEG 400 (1.98 mg/cm²) / cidofovir (4.77 mg/cm²)

Figure 5



A
B
7092 19KU X100 100μm WD39
7113 19KU X100 100μm WD39
7084 19KU X100 100μm WD39
7101 19KU X100 100μm WD39

Figure 6




Figure 7



A
B
7640 19KV X25 1mm WD39
7645 19KV X25 1mm WD39
7643 19KV X100 100µm WD39
7648 19KV X100 100µm WD39

Figure 8




Figure 9




A
B
7092 19kV X100 100µm WD39
7620 19kV X100 100µm WD39
7625 19kV X100 100µm WD39
7654 19kV X100 100µm WD39
7084 19kV X100 100µm WD39

Figure 10


19KU X25 1mm WD39
7721 19KU X25 1mm WD39
7736 19KU X100 100µm WD39
7722 19KU X100 100µm WD39



7228 19KV X4,000 1µm WD39
7723 19KV X750 10µm WD39
7724 19KV X4,000 1µm WD39

Figure 11




Figure 12 A

Figure 12 B



η (Pa.s)
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
-0.1
-0.2
NaCMC (4.77) / PEG (1.98)
NaCMC (4.77) / PEG (1.98)
NaCMC (4.77) / PEG (1.98) / CID
NaCMC (3.18) / PEG (1.98)
HPMC E15 (7.95) / PG (1.98)
HPMC E5 (11.93) / PEG (1.98)
HPMC E5 (7.95) / PEG (1.98)
HPMC E5 (7.95) / PEG (1.98) / CID
HPMC E5 (7.95) / PEG (1.98)
HPMC E5 (6.36) / PEG (1.98)
0
20.0
40.0
60.0
80.0
100.0
γ (1/s)

Figure 12 B



η (Pa.s)
0.6
0.5
0.4
0.3
0.2
0.1
0
-0.1
NaCMC (4.77) / PEG (1.98)
NaCMC (4.77) / PG (1.98)
HPMC E5 (7.95) / PEG (1.98)
HPMC E5 (7.95) / PG (1.98)
0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
γ (1/s)

Figure 13




Figure 14 A

Figure 14 B




η (Pa.s)
45.0
40.0
35.0
30.0
25.0
20.0
15.0
10.0
5.0
0
09F05 (CID) (η (Pa.s))
HEC 250 M (9.54) / PEG 400 (1.98) (η (Pa.s))
HEC 250 M (9.54) / PEG 400 (1.98) (η (Pa.s))
gel HEC M 4% (η (Pa.s))
50.0
55.0
60.0
65.0
70.0
75.0
80.0
85.0
γ (1/s)

Figure 14 B

Figure 15


η (Pa.s)
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0
09F05 (CID) (η (Pa.s))
HEC 250 HX (7.93) / PEG 400 (1.98) bis (η (Pa.s))
HEC 250 HX (7.95) / PEG 400 (1.98) bis (η (Pa.s))
gel HEC HX 3% bis (η (Pa.s))
0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
γ̇ (1/s)




Figure 15 cont.



η (Pa.s)
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0
-10.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0
γ (1/s)

Figure16

Figure16 Cont.





Figure 17


Eponges à base de cidofovir
Cidofovir dihydraté
20 mW
°C
min
METTLER TOLEDO STAR° System
Technologie Pharmaceutique ULg: METTLER